NEW YORK (GenomeWeb) — Canadian prescribing software firm GenXys HealthCare Systems said on Tuesday that it has closed a C$1.8 million ($1.4 million) round of seed financing.
Participating investors included Tydo and Telus Ventures.
GenXys — a spinout of the University of British Columbia — said it will use the funding to expand into the US market. The company's lead product is TreatGx, a software platform that integrates a patient's pharmacogenetic data with other medical information to help personalize drug selection and prevent inappropriate prescribing.
“By considering thousands of pieces of information using advanced computational analysis, our unique precision prescribing software helps find the right drug options, tailored precisely for each person, within seconds," GenXys Founder and CSO Martin Dawes said in a statement.
In mid-2017, GenXys partnered with LifeLabs to offer pharmacogenetic testing services in Canada.